Press Release - March 15, 2018
Heidelberg, Germany, March 15, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company’s AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.
|Abstract||Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)|
|Session||PO.IM02.11 – Therapeutic Antibodies, Including Engineered Antibodies 2|
|Date and Time||Monday, April 16, 2018 1:00 PM – 5:00 PM (CT)|
|Location||McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL|
Full abstract of the presentation can be accessed on the AACR website at www.aacr.org
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases.
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341